In 2001, ROVI obtained approval for the marketing of Bemiparin (Hibor®), an innovative second-generation low-molecular-weight heparin, in the leading European markets. Since then, due to ROVI’s dedication and its strategy of betting on international trade, Bemiparin has expanded its presence to more than 55 countries, as a result of strategic alliances with international partners.

Moreover, we manufacture for customers and, in this way, we export to more than 50 countries, including markets like the USA, Japan and the European Union.

English